Skip to content

Pagliuca Harvard Life Lab


Regenerative cell-therapy biotech aiming to treat people affected by blindness.

InGel team

About InGel

InGel Therapeutics is a regenerative cell-therapy biotech leveraging novel neuro-protective and neuro-repairing mechanisms to tackle retinal degeneration. We develop stem-cell therapeutics and biodegradable polymers to enhance and create therapies for eye diseases that cause retinal degeneration. Our beachhead indication is retinitis pigmentosa, while future expansion opportunities include dry age-related macular degeneration and glaucoma. The company's proprietary technology includes a stem cell therapy applied directly to the eye to halt retinal degeneration and vision loss, therefore restoring vision. This work was previously developed at Harvard Medical School (via Massachusetts Eye and Ear) by a team of engineers, cell biologists, and retinal specialists.

Join The Life Lab

The Life Lab is proud to support high-potential biotech and life-science ventures led by a Harvard affiliate.

A person on the phone inside the Life Lab office
Outside the Life Lab at night